Cost-effectiveness Analysis of Risk-factor Guided and Birth-cohort Screening for Chronic Hepatitis C Infection in the United States

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Mar 28

PMID 23533595

Citations 34

Authors

Shan Liu

Lauren E Cipriano

Mark Holodniy

Jeremy D Goldhaber-Fiebert

Affiliations

Soon will be listed here.

Abstract

Background: No consensus exists on screening to detect the estimated 2 million Americans unaware of their chronic hepatitis C infections. Advisory groups differ, recommending birth-cohort screening for baby boomers, screening only high-risk individuals, or no screening. We assessed one-time risk assessment and screening to identify previously undiagnosed 40-74 year-olds given newly available hepatitis C treatments.

Methods And Findings: A Markov model evaluated alternative risk-factor guided and birth-cohort screening and treatment strategies. Risk factors included drug use history, blood transfusion before 1992, and multiple sexual partners. Analyses of the National Health and Nutrition Examination Survey provided sex-, race-, age-, and risk-factor-specific hepatitis C prevalence and mortality rates. Nine strategies combined screening (no screening, risk-factor guided screening, or birth-cohort screening) and treatment (standard therapy-peginterferon alfa and ribavirin, Interleukin-28B-guided (IL28B) triple-therapy-standard therapy plus a protease inhibitor, or universal triple therapy). Response-guided treatment depended on HCV genotype. Outcomes include discounted lifetime costs (2010 dollars) and quality adjusted life-years (QALYs). Compared to no screening, risk-factor guided and birth-cohort screening for 50 year-olds gained 0.7 to 3.5 quality adjusted life-days and cost $168 to $568 per person. Birth-cohort screening provided more benefit per dollar than risk-factor guided screening and cost $65,749 per QALY if followed by universal triple therapy compared to screening followed by IL28B-guided triple therapy. If only 10% of screen-detected, eligible patients initiate treatment at each opportunity, birth-cohort screening with universal triple therapy costs $241,100 per QALY. Assuming treatment with triple therapy, screening all individuals aged 40-64 years costs less than $100,000 per QALY.

Conclusions: The cost-effectiveness of one-time birth-cohort hepatitis C screening for 40-64 year olds is comparable to other screening programs, provided that the healthcare system has sufficient capacity to deliver prompt treatment and appropriate follow-on care to many newly screen-detected individuals.

Citing Articles

Screening for hepatitis C in an outpatient endoscopy unit.

Rai M, Lowe C, Flemming J Can Liver J. 2022; 4(3):311-316.

PMID: 35992259 PMC: 9202776. DOI: 10.3138/canlivj-2020-0038.

Demonstration of a population-based HCV serosurvey in Ho Chi Minh City, Viet Nam: Establishing baseline prevalence of and continuum of care for HCV micro-elimination by 2030.

Kim T, Le D, Dao D, Pham T, Mize G, Phan L Lancet Reg Health West Pac. 2022; 27:100524.

PMID: 35846980 PMC: 9283666. DOI: 10.1016/j.lanwpc.2022.100524.

Population-Based Testing for Undiagnosed Hepatitis C: A Systematic Review of Economic Evaluations.

Carty P, Fawsitt C, Gillespie P, Harrington P, ONeill M, Smith S Appl Health Econ Health Policy. 2021; 20(2):171-183.

PMID: 34870793 DOI: 10.1007/s40258-021-00694-w.

Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.

Krauth C, Rossol S, Ortsater G, Kautz A, Kruger K, Herder B BMC Infect Dis. 2019; 19(1):1019.

PMID: 31791253 PMC: 6889318. DOI: 10.1186/s12879-019-4524-z.

Modelling the impact of different testing strategies for HCV infection in Switzerland.

Sadeghimehr M, Bertisch B, Schaetti C, Wandeler G, Richard J, Scheidegger C J Virus Erad. 2019; 5(4):191-203.

PMID: 31754442 PMC: 6844406.

References

Arias E . United States life tables, 2006. Natl Vital Stat Rep. 2010; 58(21):1-40. View

Fischer L, Tope D, Conboy K, Hedblom B, Ronberg E, Shewmake D . Screening for hepatitis C virus in a health maintenance organization. Arch Intern Med. 2000; 160(11):1665-73. DOI: 10.1001/archinte.160.11.1665. View

Williams I, Bell B, Kuhnert W, Alter M . Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. Arch Intern Med. 2011; 171(3):242-8. DOI: 10.1001/archinternmed.2010.511. View

Backus L, Boothroyd D, Phillips B, Belperio P, Halloran J, Mole L . A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011; 9(6):509-516.e1. DOI: 10.1016/j.cgh.2011.03.004. View

Jacobson I, McHutchison J, Dusheiko G, Di Bisceglie A, Reddy K, Bzowej N . Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364(25):2405-16. DOI: 10.1056/NEJMoa1012912. View

Walter S, Thein H, Amin J, Gidding H, Ward K, Law M . Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006. J Hepatol. 2010; 54(5):879-86. DOI: 10.1016/j.jhep.2010.08.035. View

Salomon J, Weinstein M, Hammitt J, Goldie S . Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA. 2003; 290(2):228-37. DOI: 10.1001/jama.290.2.228. View

Singer M, Younossi Z . Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med. 2002; 111(8):614-21. DOI: 10.1016/s0002-9343(01)00951-2. View

Mallette C, Flynn M, Promrat K . Outcome of screening for hepatitis C virus infection based on risk factors. Am J Gastroenterol. 2007; 103(1):131-7. DOI: 10.1111/j.1572-0241.2007.01522.x. View

10.

Siddiqui F, Ehrinpreis M, Janisse J, Dhar R, May E, Mutchnick M . Demographics of a large cohort of urban chronic hepatitis C patients. Hepatol Int. 2009; 2(3):376-81. PMC: 2716882. DOI: 10.1007/s12072-008-9086-x. View

11.

Meara E, White C, Cutler D . Trends in medical spending by age, 1963-2000. Health Aff (Millwood). 2004; 23(4):176-83. DOI: 10.1377/hlthaff.23.4.176. View

12.

Rodger A, Jolley D, Thompson S, Lanigan A, Crofts N . The impact of diagnosis of hepatitis C virus on quality of life. Hepatology. 1999; 30(5):1299-301. DOI: 10.1002/hep.510300504. View

13.

Liu S, Cipriano L, Holodniy M, Owens D, Goldhaber-Fiebert J . New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med. 2012; 156(4):279-90. PMC: 3586733. DOI: 10.7326/0003-4819-156-4-201202210-00005. View

14.

Grieve R, Roberts J, Wright M, Sweeting M, DeAngelis D, Rosenberg W . Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut. 2005; 55(9):1332-8. PMC: 1860032. DOI: 10.1136/gut.2005.064774. View

15.

Liu S, Schwarzinger M, Carrat F, Goldhaber-Fiebert J . Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients. PLoS One. 2011; 6(12):e26783. PMC: 3229483. DOI: 10.1371/journal.pone.0026783. View

16.

Chou R, Clark E, Helfand M . Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2004; 140(6):465-79. DOI: 10.7326/0003-4819-140-6-200403160-00014. View

17.

Armstrong E, Charland S . Burden of illness of hepatitis C from a managed care organization perspective. Curr Med Res Opin. 2004; 20(5):671-9. DOI: 10.1185/030079904125003485. View

18.

Ly K, Xing J, Klevens R, Jiles R, Ward J, Holmberg S . The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012; 156(4):271-8. DOI: 10.7326/0003-4819-156-4-201202210-00004. View

19.

Sherman K, Sherman S, Chenier T, Tsevat J . Health values of patients with chronic hepatitis C infection. Arch Intern Med. 2004; 164(21):2377-82. DOI: 10.1001/archinte.164.21.2377. View

20.

Sullivan P, Ghushchyan V . Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decis Making. 2006; 26(4):410-20. PMC: 2634296. DOI: 10.1177/0272989X06290495. View